RECENT NEWS

Inify Laboratories has announced a new partnership with the ProMort research team at Karolinska Institutet, aimed at transforming prostate cancer diagnostics. The primary objective of this collaboration is to improve the precision of prostate cancer diagnosis through AI-driven image analysis.

University College Dublin (UCD) researcher Dr Nicola Fletcher has received a European Research Council (ERC) Synergy Grant for her groundbreaking diagnostic project, NanoX.

The UK Health Security Agency (UKHSA) has announced that it has detected a further two cases of Clade Ib mpox. The two new cases are both household contacts of the first case, announced on 30 October. This brings the total number of confirmed UK cases to three.

Cepheid’s Xpert Mpox point-of-care test has been listed by the World Health Organization (WHO) under its Emergency Use Listing (EUL) procedure.

Diagnexia, the clinical digital pathology service of Deciphex, has opened a new, cutting-edge histopathology laboratory in Oxford.

As part of the Autumn Budget 2024, the government has allocated the NHS an extra £25.7 billion over this year and next as it looks to reform the Service and cut waiting lists.

New data presented by Roche at the 17th Clinical Trials in Alzheimer’s Disease (CTAD) congress in Madrid, Spain highlight the potential of the Elecsys Amyloid Plasma Panel and Elecsys ptau181 for ruling out Alzheimer’s disease related amyloid pathology with very good accuracy.

Digital pathology firms Gestalt and Paige have announced a strategic partnership to integrate Paige's advanced AI applications within Gestalt's award-winning PathFlow solution.

The Royal College of Pathologists (RCPath) has welcomed the 3.8% real-terms uplift over two years in support for the NHS announced by the Chancellor of the Exchequer in the recent Budget. However, in a statement responding to the Budget, the College says there needs to be a stronger investment in diagnostics, especially in pathology.

A new report from the Institute of Biomedical Science (IBMS), in partnership with PA Consulting, provides a strategic roadmap for modernising diagnostic services in the UK, while highlighting the need for technological advancements.

Researchers at the University of Helsinki have used new technology indicators of cancer cell behaviour and the architecture of the tumour and the surrounding healthy tissue to create a type of 'fingerprint’ for each patient that can be used to assess the prognosis and treatment response to cancer.

AI-biotech firm Owkin has announced MSIntuit CRC v2, a next-generation AI solution aimed at transforming the detection and treatment of colorectal cancer (CRC). It will initially launch in the US as research use only, on Roche’s navify digital pathology enterprise software.

bioMérieux is marking its world-first Centre of Reference partnership launch with St James’s Hospital, Dublin with a special free online event.

Medical Wire & Equipment has expanded its POLYWIPE range, introducing an Easy Open Stomacher Bag format. This new addition follows excellent customer feedback and the proven success of the phosphate buffer option in a variety of industries.

The first Phase 3 randomised clinical trial of an investigational mRNA norovirus vaccine will open across the UK within the next few weeks.

Caris Life Sciences, a AI TechBio company and precision medicine pioneer, has announced a multi-year research collaboration with ECOG-ACRIN Cancer Research Group.

Professional membership bodies The Royal College of Pathologists (RCPath) and the Institute of Biomedical Science (IBMS) have announced they are working on responses to the NHS 10 Year Plan consultation, as well as urging their members to contribute on an individual basis.

Bioptimus, a French startup building the reference AI foundation model in biology, has announced that its best-in-class H-optimus-0 foundation model is now integrated into Proscia’s Concentriq Embeddings, enabling data scientists and researchers in pathology and life sciences to achieve breakthroughs in AI development at unprecedented speed and scale.

A new research paper published by team from the University of Bern and Bern University Hospital in Switzerland showcases the accuracy of a new test which could improve the diagnosis of food allergies.

US diagnostics firm Access Genetics has acquired all assets of California-based company Sensible Diagnostics. Access Genetics subsidiary OralDNA will be assuming ownership of Sensible Diagnostics’ assets and will be commercialising a new point-of-care molecular diagnostics system.